抗尘肺肺纤维化的药物应用简介

摘要/Abstract

摘要： 尘肺病是由于在职业活动中长期吸入生产性粉尘,并在肺内潴留而引起的以肺组织弥漫性纤维化为主的全身性疾病。尘肺肺纤维化是由于吸入粉尘后诱导出一系列复杂的反应,从而使纤维不可逆的聚集和增多。目前还没有特殊药物能够逆转尘肺肺纤维化,治愈尘肺。尘肺肺纤维化不仅会给患者的生理和心理带来巨大的负担,还会给患者带来巨大的经济负担。所以抗尘肺纤维化的方法成为治疗尘肺的一大突破点,本文通过综述相关药物文献,以期为抗尘肺病肺纤维化临床治疗以及药物研发提供相关参考资料。

关键词: 尘肺病, 肺纤维化, 药物治疗

Abstract: Pneumoconiosis is a systemic disease mainly caused by diffuse fibrosis of lung tissue due to long-term inhalation of productive dust in occupational activities and retention in the lungs. Pneumoconiosis with pulmonary fibrosis are caused by the induction of a series of complex reactions after inhalation of dust,resulting in irreversible aggregation and an increase of fibers. At present,there are no special drugs capable of reversing pulmonary fibrosis and curing pneumoconiosis. Pneumoconiosis with pulmonary fibrosis not only imposes a huge physiological and psychological burden on patients,but also a significant economic burden. Therefore,the method of anti-pneumoconiosis with pulmonary fibrosis has become a major breakthrough point in the treatment of pneumoconiosis.This article aims to provide relevant reference materials for the clinical treatment and drug development of anti-pneumoconiosis with pulmonary fibrosis by reviewing relevant drug literature.

Key words: Pneumoconiosis, Pulmonary fibrosis, Drug treatment

中图分类号:

R135.2

赵明, 曹艳梅, 孔玉林. 抗尘肺肺纤维化的药物应用简介. [J]职业与健康, 2024, 40(24): 3452-3456.

ZHAO Ming, CAO Yanmei, KONG Yulin. Introduction to application of drugs for anti-pneumoconiosis with pulmonary fibrosis. [J]OCCUPATION AND HEALTH, 2024, 40(24): 3452-3456.

参考文献

[1] 国家卫生健康委员会规划发展与信息化司.2021年我国卫生健康事业发展统计公报[J].中国病毒病杂志,2022,12(5):321-330.
[2] 中华人民共和国国家卫生健康委员职业健康司.关于印发尘肺病防治攻坚行动方案的通知[EB/OL].(2019-07-18)[2024-01-24].http://www.nhc.gov.cn/zyjks/tongggg/201907/761eaa530f6f482bbd7b1669aecca399.shtml.
[3] LI T,YANG X Y,XU H,et al.Early Identification,Accurate Diagnosis,and Treatment of Silicosis[J].Can Respir J,2022,2022:3769134.
[4] 王焕强,李涛.尘肺病的定义与历史[J].中国职业医学,2017,44(4):485-493.
[5] HOY R F,JEEBHAY M F,CAVALIN C,et al.Current global perspectives on silicosis-Convergence of old and newly emergent hazards[J].Respirology,2022,27(6):387-398.
[6] HOY R F,CHAMBERS D C.Silica-related diseases in the modern world[J].Allergy,2020,75(11):2805-2817.
[7] 张雁林,关晓旭,毛丽君,等.我国职业医学人才培养的现况和展望[J].职业与健康,2017,33(19):2733-2736.
[8] 张曌慧,黄磊,石璐,等.中国人群尘肺病疾病负担的系统评价[J].中国循证医学杂志,2021,21(3):276-283.
[9] 蔡美钦,宇传华,胡樱.基于GBD数据的中美德尘肺病疾病负担对比[J].公共卫生与预防医学,2021,32(1):5-9.
[10] ADAMCAKOVA J,MOKRA D.New Insights into Pathomechanisms and Treatment Possibilities for Lung Silicosis[J].Int J Mol Sci,2021, 22(8):4162-4184.
[11] 张永红,张晨宁,郑涛,等.尘肺病的发病机制与药物治疗研究进展[J].中南药学,2019,17(7):1051-1055.
[12] SONG M Y,WANG J X,SUN Y L.Tetrandrine alleviates silicosis by inhibiting canonical and non-canonical NLRP3 inflammasome activation in lung macrophages[J].Acta Pharmacol Sin,2022,43(5):1274-1284.
[13] 齐恩华,赵文华,孙金英,等.应用维持剂量的汉防己甲素和羟基磷酸喹哌巩固矽肺治疗效果的研究[J].中国工业医学杂志,2001,14(1):43-44.
[14] LIU Y,ZHONG W,ZHANG J,et al.Tetrandrine Modulates Rheb-mTOR Signaling-Mediated Selective Autophagy and Protects Pulmonary Fibrosis[J].Front Pharmacol,2021,12:739220.
[15] LI J,WANG Y,WANG R,et al.Study on the molecular mechanisms of tetrandrine against pulmonary fibrosis based on network pharmacology,molecular docking and experimental verification[J].Heliyon,2022, 8(8):e10201.
[16] 李叶,孟伟明,赵雪梅.鸡内金提取物通过调节肺泡巨噬细胞自噬水平减轻尘肺大鼠肺间质纤维化的机制[J].临床和实验医学杂志,2021,20(8):792-796.
[17] WANG J,HE F,CHEN L.Resveratrol inhibits pulmonary fibrosis by regulating miR-21 through MAPK/AP-1 pathways[J].Biomed Pharmacother,2018,105:37-44.
[18] 刘树东,贾宝元,方厚华,等.复方白芪片治疗矽肺的临床疗效观察[J].中华劳动卫生职业病杂志,2000,18(3):55-56.
[19] LIU T,DAI W,LI C,et al.Baicalin Alleviates Silica-Induced Lung Inflammation and Fibrosis by Inhibiting the Th17 Response in C57BL/6 Mice[J].J Nat Prod,2015,78(12):3049-3057.
[20] 孙宁远,朱雪林,陈君.丹参化学成分抗纤维化药理作用及机制研究进展[J].中国实验方剂学杂志,2020,26(22):201-208.
[21] FENG F F,CHENG P,ZHANG H N,et al.The protective role of tanshinone IIA in silicosis rat model via TGF-β1/Smad signaling suppression,NOX4 inhibition and Nrf2/ARE signaling activation[J].Drug Des Dev Ther,2019,13:4275-4290.
[22] 丁大力,沈学彬,姚佳慧,等.中药治疗肺纤维化的研究进展[J].中草药,2021,52(22):7006-7024.
[23] GUO J W,YANG Z F,JIA Q,et al.Pirfenidone inhibits epithelial-mesenchymal transition and pulmonary fibrosis in the rat silicosis model[J].Toxicol Lett,2019,300:59-66.
[24] MISRA H P,RABIDEAU C.Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals[J].Mol Cell Biochem,2000,204:119-126.
[25] TANG Q,XING C,LI M,et al.Pirfenidone ameliorates pulmonary inflammation and fibrosis in a rat silicosis model by inhibiting macrophage polarization and JAK2/STAT3 signaling pathways[J].Ecotox Environ Saf,2022,244:114066.
[26] CAO ZJ,LIU Y,ZHANG Z,et al.Pirfenidone ameliorates silica-induced lung inflammation and fibrosis in mice by inhibiting the secretion of interleukin-17A[J].Acta Pharmacol Sin,2022,43(4):908-918.
[27] LANCASTER L H,DE ANDRADE J A,ZIBRAK J D,et al.Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis[J].Eur Respir Rev,2017,26(146):170057-170067.
[28] NOBLE P W,ALBERA C,BRADFORD W Z,et al.Pirfenidone in patients with idiopathic pulmonary fibrosis(CAPACITY):Two randomised trials[J].Lancet,2011,377(9779):1760-1769.
[29] NEIGHBORS M,CABANSKI C R,RAMALINGAM T R,et al.Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone:Post-hoc assessment of the CAPACITY and ASCEND trials[J].Lancet Resp Med,2018,6(8):615-626.
[30] MIEDEMA J R,MOOR C C,VELTKAMP M,et al.Safety and tolerability of pirfenidone in asbestosis:A prospective multicenter study[J].Resp Res,2022,23(1):139-145.
[31] MAHER T M,CORTE T J,FISCHER A,et al.Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease:a double-blind,randomised,placebo-controlled,phase 2 trial[J].Lancet Resp Med,2020,8(2):147-157.
[32] 毛翎,彭莉君,王焕强.尘肺病治疗中国专家共识(2018年版)[J].环境与职业医学,2018,35(8):677-689.
[33] WOLLIN L,MAILLET I,QUESNIAUX V,et al.Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis[J].J Pharmacol Exp Ther,2014, 349(2):209-220.
[34] PIGUET P F,VESIN C,GRAU G E,et al.Interleukin 1 receptor antagonist(IL-1ra)prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica[J].Cytokine,1993,5(1):57-61.
[35] RICHELDI L M D,DU BOIS R M,RAGHU G,et al.Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis[J].N Engl J Med,2014,370(22):2071-2082.
[36] ZHANG L,HE Y L,LI Q Z,et al.N-acetylcysteine alleviated silica-induced lung fibrosis in rats by down-regulation of ROS and mitochondrial apoptosis signaling[J].Toxicol Mech Method,2014,24(3):212-219.
[37] HUANG H P,CHEN M J,LIU F,et al.N-acetylcysteine tiherapeutically protects against pulmonary fibrosis in a mouse model of silicosis[J].Biosci Rep,2019,39(7):BSR20190681.
[38] FLEETWOOD K,MCCOOL R,GLANVILLE J,et al.Systematic Review and network meta-analysis of idiopathic pulmonary fibrosis treatments[J].J Manag Care Spec Ph,2017,23(3-b):S5-S16.
[39] RAGHU G,ROCHWERG B,ZHANG Y,et al.An official ATS/ERS/JRS/ALAT clinical practice guideline:treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline[J].Am J Resp Crit Care,2015,192(2):e3-19.
[40] BEHR J,KREUTER M,HOEPER M M,et al.Management of patients with idiopathic pulmonary fibrosis in clinical practice:The INSIGHTS-IPF registry[J].Eur Respir J,2015,46(1):186-196.
[41] ROGLIANI P,CALZETTA L,CAVALLI F,et al.Pirfenidone,nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis:A systematic review and meta-analysis[J].Pulm Pharmacol Ther,2016,40:95-103.
[42] SKVARC D R,DEAN O M,BYRNE L K,et al.The effect of N-acetylcysteine(NAC) on human cognition-A systematic review[J].Neurosci Biobehav R,2017,78:44-56.
[43] 盛晓文,胡雨奇,崔瑷.特发性肺纤维化的治疗进展[J].精准医学杂志,2021,36(6):471-476.
[44] 谢强敏. 特发性肺纤维化的药物治疗[J].世界临床药物,2013,34(1):1-6.
[45] 许银姬,金蕊,苗姝.吡非尼酮联合醋酸泼尼松治疗特发性肺纤维化的临床疗效[J].保健医学研究与实践,2022,19(2):6-8,27.
[46] 周伟勇,吴升.丹红注射液联合泼尼松龙用于特发性肺纤维化患者的临床治疗效果[J].黑龙江医药,2022,35(1):17-20.
[47] KONDOH Y,TANIGUCHI H,YOKOI T,et al.Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia[J].Eur Respir J,2005,25(3):528-533.
[48] 杨国青,于法明,刘传文.两种治疗方案对特发间质性肺炎疗效的影响[J].河南医学高等专科学校学报,2016,28(1):14-16.
[49] 罗田应. 环磷酰胺联合泼尼松治疗特发性间质性肺炎随机平行对照研究[J].临床和实验医学杂志,2015,14(1):36-38.
[50] 赵丽珂,穆冰瑶,周荣伟,等.不同免疫抑制剂及甲泼尼龙对小鼠肺间质纤维化的疗效对比[J].中国临床保健杂志,2017,20(5):579-583.
[51] 阳俊,胡克.环磷酰胺联合泼尼松治疗特发性间质性肺炎50例疗效评价[J].中国药业,2016,25(3):32-35.